Board of Directors and Scientific Advisory Board

Sean Mackay
Chief Executive Officer, Co-Founder, and Board Director

Sean Mackay is an experienced entrepreneur passionate about applying life sciences and information technology to improve healthcare delivery. He co-founded and leads IsoPlexis, a venture-backed startup focused on accelerating the fight against cancer using our predictive patient profiling platform. He has led company through foundational licensing with Yale and Caltech, venture capital financing, and building out its fantastic team, while developing applications, products, and collaborations. Previously, he also helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information. At Lifesquare, he generated business development and strategic initiatives related to partnerships across the healthcare ecosystem. Through work at Lazard and with several early-stage ventures, he developed deep experience in structuring and financing life sciences and medical device and technology companies. Sean also helped multiple public and private biotechnology and medical technology companies to manage times of strategic change.

John G. Conley
Chairman of Board

John co-founded Gilliam Capital LLC, a life science investment firm, and is a member of Launchpad Venture Group in Boston. He is a board member for three healthcare startups and works with a variety of social enterprises. He is currently the Chief Operating Officer of Entrepreneurship for All, a nonprofit that is accelerating economic and social impact through fostering entrepreneurship in mid-sized cities. He was a co-founder of the RNA interference therapeutics company Alnylam Pharmaceuticals where he held the position of Vice President, Strategy and Finance and CFO through to its successful 2004 IPO. He was Vice President of Business Development at Transkaryotic Therapies through to its acquisition by Shire Pharmaceuticals. Over ten years at Biogen he served in several marketing, business development, sales and finance positions, including Country Manager - United Kingdom and Ireland, and Treasurer. He was a Manager at the strategy-consulting firm of Bain & Company. John graduated with a BS in Economics from the University of Pennsylvania's Wharton School and an MBA from the Yale School of Management. He was a 2014 Fellow in the Advanced Leadership Initiative at Harvard University.

Gregory P. Ho
Board Director

Greg has served as the President of Spring Mountain Capital since its founding in June 2001. Previously, he was a Principal and Chief Financial Officer of McKinsey & Company, Inc. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group, as well as the identification, evaluation, and selection of traditional and alternative asset managers for over $1 billion of assets in its qualified employee plans and in-house investment office. Greg was also a Trustee of McKinsey's Profit-Sharing Retirement Plan and a member of the firm's Investment Committee. After leaving McKinsey in 1998 and prior to joining SMC, Greg was a private investor and consultant. Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine. Greg is currently a member of the Advisory Council of the Yale Entrepreneurship Institute and a member of the Investor Board of Venture for America. He received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College. He is a member of the New York Bar and the California Bar.

Daniel Wagner
Board Director

Dan serves as a Managing Director of Investments at Connecticut Innovations and is an active board member of multiple life sciences companies. Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by CuraGen Corporation, where he held a variety of scientific and operational management positions. He holds an M.B.A. and M.H.S. degree in Biomedical Sciences from Quinnipiac University, and a B.S. degree in Biology from the University of Dayton.

James R. Heath, Ph.D.
Board Director and Scientific Advisory Board Member

Jim is the Elizabeth W. Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at the University of California, Los Angeles (UCLA), and Director of the National Cancer Institute's NSB Cancer Center. He has founded or co-founded several companies, including NanoSys, MTI, Sofie Biosciences, and Indi Dx, and has served on the board of a number of organizations including the Board of Scientific Advisors of the National Cancer Institute. Jim graduated with a degree in Chemistry from Baylor University in Texas. He completed his Ph.D. in Physics and Chemistry from Rice University. He was awarded the 2000 Feynman Prize in Nanotechnology. He became a fellow of American Physical Society in 1999 and in 2009 he was named one of the seven most powerful innovators of the world by Forbes magazine.

Rong Fan, Ph.D.
Co-Founder and Chair of Scientific Advisory Board

Rong is an Associate Professor of Biomedical Engineering at Yale and a co-founder of IsoPlexis. He is the recipient of numerous awards including the Howard Temin Pathway to Independence award from NCI and the Packard Fellowship for Science and Engineering, He received a Ph.D. in Chemistry from the University of California at Berkeley, and later worked in Professor James Heath’s group at Caltech. His recent work is centered on the development of single-cell omics technologies to analyze deep functional cellular heterogeneity in human cancers and the immune system.

Ross Levine, M.D.
Scientific Advisory Board Member

Ross is the Laurence Joseph Dineen Chair in Leukemia Research, Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Ross is a physician-scientist with a specific interest in the genetics and therapy of myeloid malignancies, including the myeloproliferative neoplasms polycythemia vera, essential thrombocytosis, and primary myelofibrosis. The Ross Levine lab at Memorial Sloan Kettering Cancer Center seeks to improve understanding of the genetic basis of myeloid malignancies, with a specific focus on the role of oncogenic disease alleles in the pathogenesis of myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML).

Antoni Ribas, M.D., Ph.D.
Scientific Advisory Board Member

Antoni is a Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He is the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Vice-President of the Society for Melanoma Research (SMR) and the Chair of the Melanoma Committee at SWOG. He trained at the University of Barcelona, Spain, with postdoctoral research and clinical fellowship at UCLA. Antoni is a permanent committee member of the National Cancer Institute (NCI) grant review panels and an elected member of the American Society of Clinical Investigation (ASCI). He has published over 200 manuscripts on laboratory and clinical research in malignant melanoma.

Arnold Levine, Ph.D.
Scientific Advisory Board Member

Arnie is a widely acclaimed leader in cancer research. He is currently Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton, New Jersey. He was awarded the 1998 Louisa Gross Horwitz Prize for Biology for Biochemistry and was the first recipient of the Albany Medical Center Prize in Medicine and Biomedical Research in 2001 for his discovery of the tumor suppressor protein p53. He is the Vice Chairperson of Stand Up To Cancer’s Scientific Advisory Committee. He established the Simons Center for Systems Biology at the Institute for Advanced Study which concentrates on research at the interface of molecular biology and the physical sciences. He also chaired the National Cancer Advisory Board, which advises the National Academy of Sciences and its Institute of Medicine on cancer policy. He was elected to the National Academy of Sciences in 1991 and to its Institute of Medicine in 1995.

David Ho, M.D.
Scientific Advisory Board Member

David is a medical doctor and HIV/AIDS researcher who has made many innovative state of the art scientific contributions to the understanding and technological treatment of HIV infection. He is the scientific director and chief executive officer of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at Rockefeller University in New York City. David has been at the forefront of AIDS research for three decades. He has published over 400 papers, enabling the scientific community to understand the mechanism of HIV replication. He championed the combination anti-retroviral therapy which had earlier been developed by scientists at NIAID and Merck. This approach allowed the control of HIV replication in patients. Ho has received numerous honors and awards for his scientific accomplishments. He is the recipient of 12 honorary doctorates, including those from Columbia University and Tsinghua University. David was Time magazine's 1996 Man of the Year, and on January 8, 2001, he was presented with the Presidential Citizens Medal by President Clinton.  He received his bachelor of science in physics with highest honors from the California Institute of Technology and an MD from the Harvard-MIT Division of Health Sciences and Technology.